Lacosamide Fresenius Kabi

Lacosamide, the active ingredient in Lacosamide Fresenius Kabi, is an anticonvulsant presented as an intravenous injection for hospital use. It is indicated for the treatment of partial‑onset seizures and is employed as adjunctive therapy in patients with epilepsy, helping to reduce seizure frequency by stabilizing neuronal excitability through modulation of voltage‑gated sodium channels.

GNH USA supplies Lacosamide Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and pharmacies worldwide, with validated quality systems and cold‑chain logistics for injectable products.

Lacosamide is an anticonvulsant used in the management of seizure disorders.

- Partial‑onset seizures: Reduces seizure frequency when added to existing antiepileptic therapy. - Adjunctive therapy for epilepsy: Improves overall seizure control in patients whose seizures are not fully controlled by other medications. - Focal seizures: Provides additional seizure reduction as part of combination treatment regimens.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Nausea - Headache - Fatigue

Serious or Rare Side Effects: - Cardiac arrhythmia (including atrial fibrillation) - Severe skin reactions such as Stevens‑Johnson syndrome - Suicidal ideation or behavior - Respiratory depression - Anaphylactic reaction

When using Lacosamide injection, consider the following safety measures.

- Renal impairment: Adjust monitoring as the drug is primarily eliminated by the kidneys. - Hepatic impairment: Use with caution; hepatic dysfunction may affect drug metabolism. - Cardiac history: Monitor ECG for potential arrhythmias, especially atrial fibrillation. - Pregnancy: Category C; weigh maternal benefits against potential fetal risks. - Concomitant CNS depressants: May increase sedation and respiratory depression. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Lacosamide can interact with several medicines; the clinical relevance varies.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine): May increase plasma lacosamide concentrations. - Carbamazepine: May reduce lacosamide efficacy by inducing metabolism. - Strong CYP3A4 inducers (e.g., rifampin): May lower lacosamide plasma levels.

Moderate Interactions (Monitor Closely): - Other antiepileptics (e.g., valproate): May require dose adjustments based on therapeutic response. - Opioids: Additive central nervous system depression may occur, necessitating careful monitoring.